1 Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Gri¡ ths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999; 41: 581–3.
2 Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden. J Investig Dermatol Symp Proc. 2004; 9: 136–9.
3 Liebmann J, Born M, Kolb-Bachofen MV. Blue-light irradiation regulates proliferation and differentiation in human skin cells. Journal of Investigative Dermatology. 2010; 130: 259 – 269.
4 Fischer M et al. Blue light irradiation suppresses dendritic cells activation in vitro. Experimental Dermatology. 2013; 22: 554 – 563.
5 Weinstabl A et al. Prospective randomized study on the efficacy of blue light in the treatment of psoriasis vulgaris. Dermatology 2011; 223(3): 251–9.
6 Pfaff S et al. Prospective randomized long-term study on the efficacy and safety of UV-free blue light for treating mild psoriasis vulgaris. Dermatology. 2015; 231: 24.
Philips BlueControl is a Medical device class IIa (CE0344) for the treatment of mild to moderate psoriasis vulgaris. The product is not FDA approved and not available for purchase in the USA. Before altering or stopping any prescribed medication or using the device, patients should consult with their physician and carefully read the instructions for use. October 2016.